Source link : https://www.newshealth.biz/health-news/asthma-drug-did-not-reduce-symptom-duration-in-mild-to-moderate-covid/
Among patients with mild to moderate COVID-19, the asthma drug montelukast (Singulair) did not reduce duration of symptoms, results of the randomized controlled ACTIV-6 trial showed. After receiving montelukast or placebo for 14 days, no differences in time to sustained recovery were observed between groups (adjusted HR 1.02, 95% credible interval 0.92-1.12, P=0.63), and the […]
Author : News Health
Publish date : 2024-10-22 19:32:38
Copyright for syndicated content belongs to the linked Source.